Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons
This study suggests that docetaxel rechallenge may be an effective and tolerable later-line treatment option for patients with HER2-negative MBC, particularly those who responded to initial DBT. However, further prospective, randomized controlled research is needed to fully evaluate its impact on disease response in this patient population.
Authors
- Longgang Niu (ORCID: https://orcid.org/0000-0001-7209-7436)
- Huimin Lv (ORCID: https://orcid.org/0000-0002-4808-5782)
- Min Yan (ORCID: https://orcid.org/0000-0002-3911-748X)
- Huihui Sun (ORCID: https://orcid.org/0000-0002-8298-8766)
- Jing Wang (ORCID: https://orcid.org/0000-0001-7574-327X)
- Hao Zeng (ORCID: https://orcid.org/0000-0002-1267-0509)
- Mengwei Zhang
- Zhenzhen Liu (ORCID: https://orcid.org/0000-0002-7065-6430)
Institutions
- Zhengzhou University (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1007/s00432-025-06133-w
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05